Biosimilars in the United States: Next Steps

June 20, 2016

With biosimilar biological products moving from the lab to the marketplace, key policy and regulatory questions are being actively debated, with important implications for industry, patients, and the health care system.

This discussion will provide background on current policy and regulatory issues surrounding biosimilars, and it will consider implications for the future, answering critical questions such as: What does the future of the biosimilars market hold for patients? What information do patients and their physicians need about these medicines? What role will payers play in educating health care professionals and patients?

Our panel discussion will include the following experts:

Leah Christl, associate director for therapeutic biologics, The Food and Drug Administration (FDA)

Barbara Finck, chief medical officer, Coherus Biosciences

Brian Lehman, manager of pharmacy benefits and policy, Ohio Public Employees Retirement System (OPERS)

Leigh Purvis, director of health services research, AARP

Angus Worthing, rheumatologist and member of ACR Government Affairs Committee, American College of Rheumatology

Sarah Dash of the Alliance for Health Reform will moderate.

Please follow the briefing on Twitter: #biosimilars

The Alliance for Health Reform gratefully acknowledges the support of Coherus Biosciences for this event.

Event Details

Agenda (Adobe Acrobat PDF)
Speaker Biographies (Adobe Acrobat PDF)

Event Resources